Clinical Trials Logo

Plasma Cell Leukemia clinical trials

View clinical trials related to Plasma Cell Leukemia.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06237803 Recruiting - Multiple Myeloma Clinical Trials

European Myeloma Network (EMN) Sample Project

EMN36
Start date: December 21, 2022
Phase:
Study type: Observational

This is an observational, non-interventional, multicenter study for the prospective collection, storage and analysis of patients' biological samples. This study establishes a common international infrastructure useful to collect standard clinical variables at baseline and during treatment and to uniformly collect and store biological samples

NCT ID: NCT06045091 Recruiting - Multiple Myeloma Clinical Trials

To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL

Start date: July 4, 2023
Phase: Early Phase 1
Study type: Interventional

This study is a single-arm, open-label, dose-escalation trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of human BCMA targeted CAR-NK Cells injection, and to preliminarily observe the efficacy of the trial drug in patients with relapsed/refractory multiple myeloma or plasma cell leukemia.

NCT ID: NCT05979363 Recruiting - Clinical trials for Plasma Cell Leukemia

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia

Start date: July 1, 2023
Phase: Phase 2
Study type: Interventional

This is a single-arm, open-label study to evaluate the efficacy and safety of VRD-based regimen combined with BCMA CAR-T in transplant-ineligible patients with primary plasma cell leukemia

NCT ID: NCT05870917 Recruiting - Clinical trials for Plasma Cell Leukemia

A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia

Start date: April 25, 2023
Phase: Phase 2
Study type: Interventional

This is a single-arm, open-label study to evaluate the efficacy and safety of VRD-based Regimen (Bortezomib, Lenalidomide and Dexamethasone) combined with CART-ASCT-CART2 in Chinese patients with newly diagnosed primary plasma cell leukemia.

NCT ID: NCT05823571 Recruiting - Multiple Myeloma Clinical Trials

Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

Start date: July 6, 2023
Phase: Phase 1
Study type: Interventional

This research is being done to learn whether drug called itacitinib, which is a novel inflammation- and immune-lowering drug (immunosuppressant), can be given before and after non-myeloablative peripheral blood stem cell transplantation (PBSCT; also known as a 'mini' transplant) to help prevent certain complications such as cytokine release syndrome (CRS) for patients with blood cancers, using peripheral blood from a relative. The investigators will also examine if by using itacitinib the investigators can reduce the duration of MMF (other immune suppressive drug administration posttransplant).

NCT ID: NCT05822037 Recruiting - Multiple Myeloma Clinical Trials

CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Start date: April 12, 2023
Phase: N/A
Study type: Interventional

This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT0594CP CAR-T Cells in patients with relapsed and/or refractory multiple myeloma or Plasma Cell Leukemia

NCT ID: NCT05805605 Recruiting - Clinical trials for Myelodysplastic Syndromes

Allo HSCT Using RIC and PTCy for Hematological Diseases

Start date: May 1, 2023
Phase: Phase 2
Study type: Interventional

This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion using post-transplant cyclophosphamide (PTCy), sirolimus and MMF GVHD prophylaxis.

NCT ID: NCT05759793 Recruiting - Clinical trials for Relapsed/Refractory Multiple Myeloma

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Start date: March 30, 2023
Phase: Phase 1
Study type: Interventional

This study is a single-center, open, dose-escalation study to observe the safety and efficacy of different doses of CAR-GPRC5D in patients with R/R MM or Plasma Cell Leukemia.

NCT ID: NCT05556928 Recruiting - Multiple Myeloma Clinical Trials

Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry

CARE-Heme
Start date: July 21, 2020
Phase:
Study type: Observational [Patient Registry]

The primary purpose of this protocol is to create a registry of older (≥50 years old) patients with Hematologic Malignancies. Our main objectives include: To understand the prevalence of frailty and geriatric impairments among patients aged ≥50y and above diagnosed with a hematologic malignancy at UAB and to gather information that would lend support for future research in this vulnerable population.

NCT ID: NCT05283993 Recruiting - Multiple Myeloma Clinical Trials

A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH

Start date: July 1, 2021
Phase:
Study type: Observational

The primary aim is to establish a prospective cohort of patients with plasma cell disorders (PCDs). All of the hospitalized PCD patients who are willing to sign the informed consent form (ICF) will be included in this study. Clinical characteristics, treatment options and responses will be collected. Peripheral blood, bone marrow aspirate and urine samples before and after the treatment will banked for future research. Our team will focus on the clinical and pathological features of PCDs, the correlation between the minimal residual disease (MRD) status and prognosis, and the role of Tumor Microenvironment (TME) in the pathogenesis and progress of PCDs.